Mode
Text Size
Log in / Sign up
N/A N=316 Randomized Double-blind Treatment

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

Dry Eye Syndrome

Enrolled (actual)
316
Serious AEs
0.6%
Results posted
Dec 2009
Primary outcome: Primary: Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score — 44; 45.2; -12.6; -13.6 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Carboxymethylcellulose and Glycerin based artificial tear (Drug); Carboxymethylcellulose (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Allergan
Primary completion
Jan 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score
44; 45.2; -12.6; -13.6; -16.3; -16.6
SECONDARY
Change From Baseline at Day 30 in Schirmer Test, With Anesthesia
9.2; 8.6; 1.2; 1.2; 1.7; 1.8
SECONDARY
Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein
4.3; 4.3; 0.9; 0.9; 1.1; 0.9
SECONDARY
Patient Acceptability Score (Dryness) at Day 30
47.4; 44.6; 60.7; 57.7; 63.3; 63.8
SECONDARY
Patient Acceptability Score (Vision) at Day 30
56.8; 54.2; 65.3; 62.6; 65.4; 66.4
SECONDARY
Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein
4.0; 4.4; -1.2; -0.9; -1.3; -1.5
SECONDARY
Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein
4.9; 5.1; -1.1; -1.0; -1.7; -1.5
SECONDARY
Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score
2.8; 2.8; -0.5; -0.5; -0.7; -0.7

Summary

The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear

Eligibility Criteria

Inclusion Criteria

  • Mild, moderate or Severe Symptoms of Dry Eye

Exclusion Criteria

  • Uncontrolled systemic disease
  • Use of systemic medications affecting dry eye
  • Pregnancy or planning a pregnancy
  • Contact lens wear
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00514852). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search